Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer immunotherapy combo trial halted early – what we know

NCT ID NCT04832854

Terminated Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Mar 19, 2026 · Last updated Jun 23, 2026 · Updated 19 times

Summary

This study tested two immunotherapy drugs (tiragolumab and atezolizumab) given before and after surgery, with or without chemotherapy, for people with early-stage non-small cell lung cancer. The goal was to see if the treatment was safe and could shrink tumors enough to make surgery easier. The trial was terminated early, so only limited safety and effectiveness data are available from the 50 participants enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Cancer Center

    Duarte, California, 91010, United States

  • Columbia University

    New York, New York, 10032-3725, United States

  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña, 15006, Spain

  • Corporacio Sanitaria Parc Tauli

    Sabadell, Barcelona, 08208, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, 28222, Spain

  • ICO L'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Kantonsspital Baden

    Baden, 5404, Switzerland

  • Kantonsspital Graubünden Medizin Onkologie

    Chur, 7000, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, 9007, Switzerland

  • Kantonsspital Winterthur

    Winterthur, 8401, Switzerland

  • NYU Cancer Center

    New York, New York, 10016, United States

  • Peter Maccallum Cancer Institute

    Melbourne, Victoria, 3000, Australia

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • St. Vincent's Hospital

    Gyeonggi-do, 16247, South Korea

  • Sunshine Coast University Hospital

    Birtinya, Queensland, 4575, Australia

  • University of Southern California

    Los Angeles, California, 90033, United States

  • UniversitätsSpital Zürich

    Zurich, 8091, Switzerland

  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, 08035, Spain

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Winthrop Univ Hospital

    Mineola, New York, 11501, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tiragolumab and atezolizumab (immunotherapy drugs), with or without platinum-based chemotherapy

What this could lead to

If successful, this approach could improve outcomes for patients with early-stage lung cancer by shrinking tumors before surgery and reducing the chance of cancer coming back afterward.

What could go wrong

The trial was terminated early, so results are limited. Immunotherapies can cause immune-related side effects, and adding chemotherapy increases toxicity. The small size (50 participants) and early phase mean any benefits are uncertain.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC) NON-SMALL CELL LUNG CANCER (NSCLC)